Thrombophilias and adverse pregnancy outcome

Haematologica

Volumn 88, Issue 7, 2003, Pages 729-731

  Many, Ariel ^a   Kupferminc, Michael J ^a  

^a LIS MATERNITY HOSPITAL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; FEMALE; HUMAN; HYPERCOAGULABILITY; INTRAUTERINE GROWTH RETARDATION; PREECLAMPSIA; PREGNANCY COMPLICATION; SOLUTIO PLACENTAE; THROMBOPHILIA; THROMBOSIS;

ABRUPTIO PLACENTAE; FEMALE; FETAL DEATH; FETAL GROWTH RETARDATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; THROMBOPHILIA;

EID: 0037483678     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Facchinetti F, Marozio L, Grandone E, Pizzi C, Volpe A, Benedetto C. Thrombophilic mutations are a main risk factor for placental abruptio. Haematologica 2003;88:785-8.
2. Roberts JM, Taylor RN, Musici TJ, Rodgers GM, Hubel CA, McLaughlin MK. Pre-eclampsia: an endothelial cell disorder. Am J Obstet Gynecol 1989;161:1200-4.
3. Salafia CM, Pezzulo JC, Lopez-Zeno JA, Minior VK, Vintzileos AM. Placental pathologic features of preterm preeclampsia. Am J Obstet Gynecol 1995;173:1079-105.
4. Shanklin DR, Sibai BM. Ultrastructural aspects of preeclampsia. Am J Obstet Gynecol 1989;161:735-41.
5. Khong TY, Pearce JM, Robertson WB. Acute atherosis in preeclampsia: maternal determination and fetal outcome in the presence of the lesion. Am J Obstet Gynecol 1987;157:360-3.
6. Salafia CM, Minior VK, Pezzulo JC, Popek EJ, Rosenkrantz TS, Vintzileos AM. Intrauterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. Am J Obstet Gynecol 1995;173:1049-57.
7. Green JR. Placenta previa and abruptio placentae. In: Creasy RK, Resnik R. editors. Maternal Fetal Medicine: principles and Practice. Philadelphia: W. B. Saunders; 1994. p. 609-10.
8. Infante-Rievard C, David M, Gauthier R, Ribard GE. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. N Engl J Med 1991;325:1063-6.
9. Dekker GA, Sibai BM. Etiology and pathophysiology of preeclampsia: current concepts. AJOG Review. Am J Obstet Gynecol. 1998;179:1359-75.
10. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001;98:1041-4.
11. Mousa HA, Alfirevic Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome? Hum Reprod 2000;15:1830-3
12. Sikkema JM, Franx A, Bruinse HW, van der Wijk NG, de Valk HW, Nikkels PG. Placental pathology in early onset preeclampsia and intra-uterine growth restriction in women with and without thrombophilia. Placenta 2002;23:337-42.
13. Arias F, Romero R, Joist H, Kraus FT. Thrombophilia: a mechanism of disease in women with adverse pregnancy outcome and thrombotic lesions in the placenta. J Matern Fetal Med 1998;7:277-86.
14. Dekker GA, de Vries JIP, Doelitzsch PM, Huijgens PC, Blomberg von BME, Jakobs C, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995;173:1042-8.
15. Kupferminc MJ, Eldor A, Steinman N, Many A, Bar-Am A, Jaffa A, et al. Increased frequency of the genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999;340:9-13.
16. Lima F, Khamashta MA, Buchanan NM, Kerslake S, Hunt BI, Hughes GRV. A study of sixty pregnancies in patients with the antiphospholipid syndrome. Clin Exp Rheumatol 1996;14:131-6.
17. Polzin WJ, Kopelman JN, Robinson RD, Read JA, Brady K. The association of antiphospholipid antibodies with pregnancy complicated by fetal growth restriction. Obstet Gynecol 1991;78:1108-11.
18. Murphy RP, Donoghue C, Nallen RJ, D'Mello M, Regan C, Whitehead AS, et al. Prospective evaluation of the risk conferred by factor V Leiden and the thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000;20:266-70.
19. Martinelli I, Taioli E, Cetin I, Marinoni A, Gerosa S, Villa MV, Bozzo M, Mannucci PM. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000;343:1015-8.
20. Many A, Elad R, Yaron Y, Eldor A, Lessing JB, Kupferminc MJ. Third-trimester unexplained intrauterine fetal death is associated with inherited thrombophilia. Obstet Gynecol 2002;99:684-7.
21. Grandone E, Margaglione M, Colaizzo D, d'Addedda M, Cappucci G, Vecchione G, et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997;77:822-4.
22. Deitcher SR, Park VM, Kutteh WH. Methylene tetrahydrofolate reductase 677C T mutation analysis in Caucasian women with early first trimester recurrent pregnancy loss. Blood 1998;92 Suppl 1:117b[abstract].
23. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-3.
24. Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet drugs for prevention of pre-eclampsia and its consequences:systematic review. Br Med J 2001;322:329-33.
25. North RA, Ferrier C, Gamble G, Fairley KF, Kincaid-Smith P. Prevention of preeclampsia with heparin and antiplatelet drugs in women with renal disease. Aus NZ J Obstet Gynaecol 1995;35:357-62.
26. Kupferminc MJ, Fait G, Many A, Lessing JB, Yair D, Bar-Am A, et al. A. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001;20:35-44.